Platelet Hyperreactivity Project

Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00976196

Acronym

PHP

Enrollment

110

Registered

2009-09-14

Start date

2009-01-31

Completion date

2010-01-31

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet Reactivity

Keywords

Aspirin, Blood platelets, proteomics, Platelet reactivity

Brief summary

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.

Detailed description

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype. Main objective: * to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients Secondary objectives: * to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin * to determine genetic polymorphisms associated with platelet hyperreactivity

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Documented symptomatic ischemic atherothrombotic disease treated by aspirin.

Exclusion criteria

* Known platelet disorder * Chronic treatment by antiplatelet drugs other than aspirin * Chronic anticoagulant treatment * Chronic non steroidal anti-inflammatory drug treatment * Active cancer * Treatment with serotonin reuptake inhibitors

Design outcomes

Primary

Measure	Time frame	Description
proteome profile of platelet hyperreactivity	cross sectional	to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary

Measure	Time frame
platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin	cross sectional

Other

Measure	Time frame
genetic polymorphisms associated with platelet hyperreactivity	cross sectional

Countries

Switzerland

Outcome results